NCT03454763View on ClinicalTrials.gov

Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

618

Participants

Timeline

Start Date

May 26, 2016

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions
Neuroendocrine Tumors
Interventions
DRUG

PRRT every 5 weeks

PRRT (radiolabelled somatostatin analogues) every 5 weeks for 5 cycles

DRUG

PRRT every 8-10 weeks

PRRT (radiolabelled somatostatin analogues) every 8-10 weeks for 5 cycles

Trial Locations (1)

47014

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER